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1 Introduction  
Soft tissue sarcomas (STSs) are a heterogeneous group of malignant tumours with 
mesenchymal differentiation. They usually present as a painless enlarging mass 
without systemic symptoms. 
STSs are primarily treated with a wide-margin surgery trying to preserve limb function. 
Surgery can be combined with both chemotherapy and radiotherapy. However, 
surgery remains the only curative treatment. Inadequately resected STSs tend to 
reoccur locally while high-grade STSs are prone to develop pulmonary metastasis and 
have worse outcome than low-grade tumours. 
To initiate correct treatment, a biopsy, most often a core needle biopsy (CNB) should 
be performed on all STS suspect masses before any treatment. The biopsy method of 
choice should be able to differentiate STSs from both non-mesenchymal tumours and 
benign soft tissue tumours (STTs) to avoid surgery with inadequate margins. In 
addition, the biopsy should be able to separate STSs into low- and high-grade STSs to 
enable identification of patients who might benefit from neoadjuvant treatment.  
Identification of certain STS subtypes is also beneficial for treatment planning. The final 
histologic diagnosis and grading are based on microscopic evaluation of the resected 
surgical specimen. 
In this study we aim (i) to evaluate the accuracy of CNB in diagnosing and grading 
primary STSs located in the trunk and extremities treated by the soft tissue sarcoma 
group at Helsinki University Central Hospital (HUCH) during 2000-2012 using a 
modified 4-grade Broders grading system (1), (ii) to recognize any major grading or 
diagnostic errors and their underlying reason and (iii) to evaluate the possible effects 
of the errors on the treatment according to current treatment guidelines at HUCH. 
2 Literature review 
2.1 Overview 
Most STSs occur in adults and they account for approximately 1 % of all malignant 
tumours diagnosed in adulthood (2), whereas STSs represent 7 % of all malignant 
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tumours in patients younger than 20 years (3). Rhabdomyosarcoma (40 %) and 
fibrosarcoma (29 %) are the two most common STSs in children younger than 20 years 
(3), whereas liposarcoma (29 %) and malignant fibrous histiocytoma/undifferentiated 
pleomorphic sarcoma (25 %) are the most common STSs in the extremities of adults 
(4). 
STSs are most often located in the extremities (59.5 %) followed by the trunk (17.9 %) 
(5). However, they can occur virtually anywhere in the body outside bone. Seventy-six 
percent of STSs of the extremity are situated beneath the deep fascia (4). 
2.2 Aetiology 
The aetiology of STSs is largely unknown and in most cases an underlying cause cannot 
be identified. Neurofibromatosis type I, Li-Fraumeni syndrome, hereditary 
retinoblastoma, chronic lymphedema, Epstein-Barr virus and exposure to ionizing 
radiation are best known predisposing factors for STSs (6). In addition, certain 
chemicals have been indicated to increase the risk for STSs (7). 
Radiotherapy, in a cohort study, increased the risk for STSs, with a peak incidence of 
STSs at 10-14 years after radiotherapy (8). About three times more sarcoma-cases 
(including both bone and soft tissue sarcomas) than expected were reported starting 
ten years after exposure to radiotherapy. Patients treated with radiotherapy when 
younger than 55 years were in particular at an increased risk of developing a STS later 
in life (8). About four times more cases of sarcomas than expected were reported for 
this group compared with only approximately two times more cases reported for 
patients older than 55 years starting ten years after treatment with radiotherapy. 
The most common subtypes of post-irradiation sarcomas, as reported in a study of a 
nationwide registry of Finland from 1953 to 1988 (9), are osteosarcoma, malignant 
fibrous histiocytoma and fibrosarcoma. Most tumours (31/33) were high-grade 
sarcomas. Only 29 % of patients with post-irradiation sarcoma in the same study were 
alive after five years. In another study, of patients from 1973 to 1997 with post-
irradiation sarcomas of the breast, angiosarcoma was the most common subtype (56.8 
%) (10). 
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2.3 Classification 
Histologically STSs are mainly classified according to their resemblance to 
differentiated mesenchymal tissue with further subgroups (11). In certain cases 
however, the tumour tissue is not related to the differentiated tissue as is the case 
with synovial sarcoma (12). Also STSs do not arise from fully differentiated tissue, but 
from mesenchymal stem cells (13). 
More than 50 STS subtypes are described in the current WHO classification of bone 
and soft tissue tumours from 2013 (14). To aid classification, a number of tissue-
specific immunohistochemical markers are in clinical use (11). They are particularly 
useful for typing differentiated sarcomas but do not always provide definite evidence 
(11). 
Genetically STSs can be divided into two groups. Certain STSs have an abnormal 
karyotype where no specific changes can be identified (group I), whereas for quite a 
few STSs specific translocations and gene mutations (group II) have been identified 
that can be used for classification (15). An example is synovial sarcoma in which a 
specific translocation t(X;18)(p11.2;q11.2) can be found in more than 90 % of patients 
(11). 
2.3.1 Grading 
For grading of STSs, the most common system used, is the French grading system 
(FNCLCC) (16). It is a three-grade system taking into account tumour differentiation, 
amount of mitoses and necrosis. However, a modified 4-grade Broders system, where 
grade one and two are low-grade tumours and grade three and four are high-grade 
tumours (1), is used at HUCH. It takes into account tumour cellularity, pleomorphism, 
nuclear atypia, necrosis, mitotic activity and in certain cases the histologic subtype 
(17). Compared with a 3-grade system, a 4-grade system is able to predict outcome 
more accurately in patients with high-grade tumours (18). STSs can also be grouped 
namely into low- and high-grade tumours. 
Grading is very useful for predicting overall survival and the risk for metastatic disease 
(4, 16) and thus find patients eligible for (neo)adjuvant treatment. However, not all STS 
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subtypes are gradable. These include clear cell sarcoma and soft-part alveolar sarcoma 
that are by definition high-grade tumours and angiosarcoma where grade does not 
correlate with the normal parameters used for grading (11). 
2.4 Growth pattern 
Enneking and colleagues summarized the growth pattern of STSs in an article from 
1981 (19). STSs expand spherically, pushing surrounding tissue out of the way. This is 
called pushing border growth. A zone of reactive tissue, a so called pseudocapsule, 
develops around the tumour and the compressed tissue. High-grade STSs often 
infiltrate into surrounding tissue, though some low-grade STSs also have this growth 
pattern (20). This infiltrative growth pattern has been recognised as a risk factor for 
metastatic spread (RR 4.6, p = 0.001) and local reoccurrence (RR ∞, p = 0.001; no STS 
with a pushing border reoccurred locally). Centrally a necrotic core often develops due 
to the tumour outgrowing the blood supply (21). 
Tumour tissue from low-grade STSs is seldom found in surrounding normal tissue but 
high-grade tumour tissue is frequently found there (19). Rather than being direct 
extensions of the tumour, they may be short distance metastases, so called skip 
metastases. They are often situated close to blood vessels.  
STSs seldom perforate fascia and thus they do not normally spread from one anatomic 
compartment to another (19). When this happens, it happens mainly around blood 
vessels or because of improper surgery. Likewise tumour spread to bone is very 
uncommon. 
Lungs are the most frequent location of STS metastases. Nineteen percent of patients 
with extremity STSs develop pulmonary metastases at some point (22). Lymph node 
metastases are uncommon. Only 3.7 % of patients with extremity STSs develop 
metastatic disease to lymph nodes (23). However, angiosarcoma, clear cell sarcoma, 
embryonal rhabdomyosarcoma and epithelioid sarcoma are more likely to spread to 
lymph nodes (23). In addition, myxoid liposarcoma is known to send metastases to 
extra-pulmonary soft tissue sites (24). Thirteen months was reported as the latent time 
from diagnosis to development of metastatic disease in the largest study of extremity 
STSs (4). 
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2.5 Prognostic factors 
STSs have had low survival rates but prognosis has improved. Patients treated at HUCH 
for extremity and trunk STSs between 1987 and 2002 had 5-year survival rates of 75 % 
(95 % CI 0.70−0.80) and 10-year survival rates of 71 % (95 % CI 0.64−0.76) (25). In 
another study of 1 041 patients with extremity STSs, 5-year disease-specific survival 
was 76 % (4). However, a significant difference in 5-year disease-specific survival rates 
was reported between low-grade (94.7 %) and high-grade tumours (65.7 %; p = 
0.0001). 
Grade is the most important prognostic factor for 5-year overall survival with a relative 
risk of 4.0 (95 % CI 2.5−6.6) (4). Other factors, recognized in the same study, with 
negative impact on 5-year disease-specific survival were deep location (RR 2.8), 
diameter greater than 5 cm (RR 2.1), proximal location in lower extremities (RR 1.6), 
microscopically positive surgical margins (RR 1.7) and local recurrence (RR 1.5). 
Leiomyosarcoma (RR 1.9) and malignant peripheral nerve sheath tumour (MPNST) (RR 
1.9) were associated with worse 5-year disease-specific survival (4). Another study of 
997 patients with extremity STSs identified high grade, deep tumour location, large 
size, positive surgical margins and both MPNST and synovial sarcoma as adverse 
prognostic factors for disease-specific survival (26). Grade was also reported in this 
study as the most important adverse factor for disease-specific survival: grade two and 
three tumours had relative risks of 5.37 and 8.80 respectively compared with grade 
one tumours. 
Metastatic disease is associated with low survival rates. Pisters and colleagues 
reported that only 28 % of patients who developed metastatic disease were alive at 
the last follow-up (4). The median follow-up period was 3.95 years among survivors in 
the above mentioned study. The median lifetime was 14.5 months from discovery of 
metastatic disease. Patients with a primary tumour greater than 10 cm in diameter 
were identified as having worse post-metastatic survival (RR 1.5). 
The most important prognostic factor associated with an increase in the risk for 
metastatic disease is high grade, with a risk ratio of 4.3 (95 % CI 2.6−6.9) compared to 
low grade tumours (4). Other adverse factors for metastatic disease, were presence of 
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locally recurrent disease (RR 1.5), deep location (RR 2.5), large tumour size (RR 1.9 for 
5-10 cm tumours and RR 1.5 for >10 cm tumours) and leiomyosarcoma (1.7). Patients 
with liposarcomas were less likely to develop metastatic disease (RR 0.64). Size, grade 
and histologic subtype were also reported as significant prognostic factors for 
metastatic disease in another study (26). It also identified grade as the most important 
risk factor for metastatic disease, with risk ratios of 4.49 for grade two and 6.98 for 
grade three STSs (compared to grade one STSs).   
Local recurrence is a common trait of STSs. Five-year local control of STSs of the trunk 
and extremities was 76.4 % among patients treated at HUCH between 1987 and 1997 
(27). When local treatment was adequate, 84.2 % of patients with STSs did not develop 
a local relapse. A study reported a median time of 17 months for development of local 
recurrence (4). A positive surgical margin was identified as an important adverse 
factor, with a risk ratio of 1.8 (95 % CI 1.3−2.5) (4). The study also reported that 
patients older than 50 years (RR 1.6), with previous locally recurrent STS (RR 2) or with 
fibrosarcoma (RR 2.5) or MPNST (RR 1.8) were more likely to develop a local 
recurrence. Positive surgical margins, histologic subtype and lack of radiotherapy were 
also reported as adverse prognostic factors for local recurrence in another study (26). 
2.6 Diagnosis 
At diagnosis most STSs appear as painless enlarging masses without systemic 
symptoms. Symptoms mainly develop late due to compression of adjacent tissue. 
Nineteen percent of STS patients experience pain (4) due to compression of nerves. 
STS may also disturb joint function and vein and lymphatic vessel compression may 
cause swollenness. At initial diagnosis 53 % of STSs are already greater than 5cm in 
diameter (4). 
To initiate correct treatment of STSs, a preoperative biopsy should be done. At HUCH it 
is most often a CNB. The biopsy should be able to differentiate benign STTs from STSs, 
low-grade from high-grade STSs and non-mesenchymal from mesenchymal tumours. 
Identifying certain STS subtypes is beneficial for treatment planning. These include 
synovial sarcoma and myxoid liposarcoma. Imaging is used to evaluate the extent and 
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spread of the tumour, its location to neighbouring neurovascular structures and for 
staging as well as to evaluate malignancy. 
At HUCH the CNB is obtained under ultrasound-guidance. However, in patients where 
the tumour is difficult to access, CT- or MRI-guidance may be used. A fine-needle 
aspiration (FNA) specimen is obtained simultaneously but it is of limited value in 
diagnostics of STSs at HUCH. The CNB and FNA specimen are then evaluated by an 
experienced musculoskeletal pathologist to determine diagnosis and grade. Patients 
with myxoid liposarcoma at HUCH undergo a full-body CT-scan, while all patients with 
a high-grade STS undergo a CT of the thorax before surgery. A plain radiograph of the 
thorax is obtained preoperatively of patients with a low-grade STS. 
2.6.1 Biopsy 
Open biopsy has been regarded as the golden standard for diagnosis of STS (21). It was 
reasoned that core needle biopsy did not provide adequate tissue for diagnosis and 
grading (28). In particular evaluating mitotic activity and necrosis accurately from CNB 
specimens can be difficult (6). Thus grade is often underrepresented in CNBs. 
Non-diagnostic CNB rates between 6 and 22.5 % are reported in literature (21, 29, 30, 
31, 32, 33). The CNB can easily be repeated if the original CNB is non-diagnostic. A 
number of factors have been identified affecting the rates of non-diagnostic CNBs. 
Image-guided CNBs more often obtained adequate tissue compared to free-hand CNBs 
with adequate tissue obtained in 100 % and 86 % of CNBs respectively (p < 0.01) (34). 
The image-guidance method, however, does not affect diagnostic yield (p = 0.07867) 
(33). A study recommended obtaining four CNB specimens from STTs to optimize 
diagnostic yield, obtaining more than four CNB specimens did not improve diagnostic 
yield (35). The same study found that specimen length correlated with diagnostic yield: 
< 5mm, 5−10mm and > 10mm had diagnostic yields of 42 %, 61 % and 82 % 
respectively (p < 0.001). The study also reported that larger musculoskeletal tumours 
had better diagnostic yields: tumours < 2 cm, tumours 2−5 cm and tumours > 5 cm had 
diagnostic yields of 54 %, 75 % and 86 % respectively (p < 0.001). Diagnostic yield in 
heterogeneous STTs is lower compared to homogenous STTs (81.4 vs 97.5 %, p = 
0.0036) (33). 
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CNB has acceptable accuracy rates (78−99 %) and low complication rates (0−2.6 %) in 
diagnosis of soft tissue and musculoskeletal tumours (Table I). While open biopsy in 
comparison, is more accurate with accuracy rates from 95 to 100 % (21, 40, 43, 49, 50), 
a high complication rate (15.9 %) was described in a study of 597 patients (51).The 
complications consisted of skin, bone and soft tissue problems. In 16.6 % of all STT 
biopsies in the same study, treatment was altered due to issues with the biopsy (p < 
0.001). It is also noteworthy that CNB costs a fraction of the price of open biopsy (39).  
Studies have further evaluated CNB as a diagnostic tool for diagnosis of STTs and 
musculoskeletal tumours and demonstrated that very few false-positive results occur 
with specificity rates of 82 to 100 % reported (Table I). Meanwhile false-negatives do 
happen more often with sensitivity rates of 79 to 100 %. Likewise studies that have 
reported on the accuracy of grading STSs, have generally noted satisfactory accuracy 
rates from 83 to 100 % (Table I), with no STSs being falsely designated as high-grade 
(48). Tumours falsely designated as low-grade do occur more often with sensitivity 
rates of 81 and 89 % reported (40, 48). The low sensitivity rates have been explained 
by the small amount of tissue CNB provides, thus underrepresenting mitoses and 
necrosis. On the other hand, CNB enables collection of tissue from multiple locations 
whereas open biopsy only enables sampling from a superficial area that may not be 
representative of the core tumour (36, 43). STS subtype is accurately specified from 56 
to 100 % (Table I) of CNB specimens. However, subtyping has limited value in initial 
clinical decision making with the exception of myxoid and synovial sarcomas. 
Most importantly CNB has been shown to initiate definitive treatment and enable one-
stage surgery for STSs. Of patients undergoing CNB, 95 % were treated with a one-
stage surgery (28). A study reported on biopsy errors in bone and soft tissue tumours 
and identified seven patients of 223 in whom a benign tumour turned out malignant 
after surgery (29). Nevertheless, they were all correctly treated. In addition 24 errors in 
grade or subtype were found in the same study but neither did they affect treatment. 
Another study found only minor histopathological errors in 1.1 % of patients with no 
impact on treatment (31). 
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Table I Summary of studies of CNB accuracy in diagnostics of soft tissue and musculoskeletal tumours 
Study Grading 
Values based on 
comparison between 
Number of 
tumours with CNB 
(STSs) 
Accuracy % Sensitivity % Specificity % 
Grading 
accuracy % 
STS Subtype 
% 
CNB 
Complications % 
 
Ball et al 1990 (36) NS STSs − Other 52 (45) 94 93 - 88 85 1.9†‡  
Barth et al 1992 (37) NS Sarcomas − Benign 38 (16) 96 100 91 100 - 2.6†§  
Fraser-Hill et al 1992 (38) - Primary tumours 92 83 - - - - -  
Skrzynski et al 1996 (39) - STTs 62 78 - - - - 1.6†  
Heslin et al 1997 (40)* LG-HG Malignant − Benign STTs 56 95 93 100 93 - -  
Serpell et al 1998 (41) - Malignant − Benign STTs 31 (14) 84 94 100 - 100 -  
Yao et al 1999 (42) - STTs 141 82 - - - - -  
Welker et al 2000 (43) NS Malignant − Benign STTs 161 (83) 92.4 81.8 100 88.6 - 1.1  
Hoeber et al 2001 (44)* NS STSs − STTs 259 (180) 99.2† 99.4 98.7 84.9 79.9 -  
Torriani et al 2001 (45) - Musculoskeletal tumours 48 97 96 100 - - 0  
Ray-Coquard et al 2003 (46)* - Sarcomas − Other 103 (65) 95 92 100 - - 1  
Yang et al 2004 (47) NS 
Primary musculoskeletal 
tumours 
42 93 - - 83 - - 
 
Altuntas et al 2005 (48) - STTs 50 80 - -     
Mitsuyoshi et al 2006 (32)* - Malignant − Benign STTs 163 94 - - - - 0.61†  
Ogilvie et al 2006 (30) - 
Primary musculoskeletal 
tumours 
58 - 72 98 - - - 
 
Woon et al 2008 (28) - STSs − STTs 68 (23) 83.6 91.3 100 - 70 -  
Narvani et al 2009 (34) - STTs 111 88.29 - - - - -  
Sung et al 2009 (33) - STTs 122 79,1 - - - - 0  
Kasraeian et al 2010 (21) AJCC STTs 57 81 79 82 - - -  
Strauss et al 2010 (48) FNCLCC STSs − STTs 376 (225) 97.6 96.3 99.4 86.3 88.6 0.40‡  
Verheijen et al 2010 (49) - STSs − STTs 116 (90) 78 - - - 56 -  
Pohlig et al 2012 (50) - STSs 46 (13) 84.6 81.8 100 - - -  
*Excluded non-diagnostic CNBs from study ; †Calculated afterwards using data provided in study; ‡Intra- or retroperitoneal tumours; §Fine-needle aspiration specimen obtained simultaneously  
AJCC = American Joint Committee on Cancer; CNB = Core-needle biopsy; FNCLCC = French Federation of Cancer Centres Sarcoma Group; HG = High-grade; LG = Low-grade NS = Not specified STS = Soft tissue sarcoma; 
STT = Soft tissue tumour 
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There are, however, a few studies that indicate that CNB would not provide adequate 
information for correct treatment.  One recent prospective study reported that CNB 
would only provide enough information in 49.1 % of patients to initiate correct 
treatment (21). Open biopsy proved clinically useful in all patients. Another study 
found only 63 % of STS CNBs clinically useful (30). These articles however, do not state 
why clinical usefulness was so low. 
Studies have identified a number of factors affecting the accuracy of CNBs in 
diagnostics of STSs. Image-guided CNBs had a higher diagnostic accuracy (95 %) 
compared to free-hand CNBs (78 %) in a non-randomized study (p ≤ 0.025) (34). 
Another study reported that the number of CNB specimens did not influence grading 
accuracy (29). 
Histological factors affecting CNB accuracy include myxoid tumour nature. In a study 
only 11 % of the CNBs of myxoid tumours were clinically useful, compared with 80 % of 
CNBs of non-myxoid tumours being useful (p = 0.001) (30). Higher rates of diagnostic 
errors were also found in another study in CNBs of myxoid tumours (p = 0.021) (29). 
This is a result of the small amount of cells in the rich connective tissue. Papers have 
also identified well-differentiated liposarcomas as often being misdiagnosed (28, 32, 
48). It is noteworthy that these tumours can be challenging to differentiate from 
benign lipomas even in the surgical specimen (36). More importantly, well-
differentiated liposarcomas are treated with enucleation; a faulty diagnosis does not 
affect treatment. 
A recent study suggested that the grade assigned by CNBs is not ideal for evaluating 
patient prognosis (52). The grade established (FNCLCC) for extremity spindle-cell STSs 
by CNB, did neither correlate with metastasis free survival (p = 0.59) nor disease free 
survival (p = 0.50). Meanwhile open biopsy was able to predict both disease free 
survival (p = 0.001) and metastasis free survival (p < 0.001). 
Fine needle aspiration cytology (FNAC) is an even less-traumatic and cheaper biopsy 
method than CNB. It is generally considered insufficient for diagnosis of STTs, with 
accuracy rates from 38 to 88 % reported for malignancy (21, 37, 46, 49). In all of the 
above mentioned studies, evaluation of CNBs provided better accuracy rates. 
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Evaluating tumour architecture from FNA specimens is not possible and may not 
provide enough material for further study (53). For diagnosis of recurrent high-grade 
STSs FNAC may be able to provide enough material (37). It can also be useful in cases 
where the tumour is situated close to neurovascular structures. 
Certain STS treatment centres however, use FNAC routinely in diagnostics of sarcomas. 
Studies from these treatment centres have reported sensitivity rates from 86 to 92 % 
for mesenchymal malignancy (when excluding inadequate specimens) (54, 55, 56). 
Ninety percent of STSs were correctly graded as high- or low grade STSs (55).  STS 
subtyping based on FNA specimens is generally not possible (54). In the same study, 83 
% of the FNA specimens were able to guide definite treatment of STSs. In one study, 11 
of 271 patients had an incorrect malignant diagnosis set by the FNA specimen when 
the tumour was benign (56). Consequently seven of these eleven patients had 
inappropriate surgery with wide or radical margins. 
Kilpatrick and colleagues recognized on site-evaluation as the main strength of FNAC 
and recommended FNAC mainly for diagnosis of STTs when the specimen can be 
evaluated on-site (54). Otherwise they thought CNB is preferable, to guarantee enough 
material for further studies. 
2.7 Treatment 
2.7.1 Surgical treatment 
According to current knowledge the best choice of initial treatment for STSs is surgery 
with a wide margin that preferably preserves limb function. This is because a positive 
surgical margin is the most important adverse factor for local recurrence (57) and the 
wider the margin the better local control (27). In addition, any biopsy tracts have to be 
removed, because of contamination when obtaining the CNB specimen (58). Thus 
correct classification of STSs based on the preoperative biopsy is important to enable 
adequate surgery with a wide margin. At the time of writing, surgery is the only 
curative treatment for STSs. 
A study from 1981 by Enneking and colleagues examined the impact of STS grade on 
the margins required to obtain local control (19). They concluded that high-grade STSs 
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require more radical surgery than low-grade tumours to obtain similar local control 
rates (19). In addition they concluded that while limb-sparing surgery with wide 
margins is usually possible for intracompartmental STSs, amputation is required for 
extracompartmental STSs to obtain adequate margins. 
In a more recent study an adequate margin was defined as 2−3 cm as measured from 
the reactive zone because it provided reasonable local control regardless of grade (27). 
With a smallest margin of 2.5 cm, 89.2 % achieved local control. However, a smaller 
margin is adequate if it contains an intact fascia. Surgery with negative margins alone 
in small (≤ 5 cm), superficial STSs was reported to result in good local control and 
overall survival in a non-randomized prospective study (59). 
 2.7.2 (Neo)adjuvant therapy 
Radiotherapy and chemotherapy can be administered both as adjuvant and 
neoadjuvant treatment. Neoadjuvant therapy is indicated in patients in whom imaging 
shows surgery would result in intralesional removal of the tumour or amputation. 
Neoadjuvant treatment may shrink the tumour and thus improve the chances for 
marginal or limb sparing-surgery (60). Correct identification of malignant mesenchymal 
neoplasms and grade is thus imperative to find patients eligible for neoadjuvant 
therapy. 
External-beam radiotherapy administered post-operatively improved local control in 
both high- and low-grade STSs (p = 0.0028) in a randomized study (61). However, the 
study found no statistically significant improvement in overall survival. Another 
randomized study, where radiotherapy was administered as brachytherapy for fully 
resected STSs, found statistically significant improvements in local control limited to 
high-grade STSs (p = 0.0025), in the group receiving radiotherapy (62). No statistically 
significant improvements in overall survival or decrease in metastatic disease were 
observed. A similar randomized study analysing the impact of brachytherapy on low-
grade STSs reached similar results, failing to demonstrate an improvement in local 
control (63). As a result, Yang and colleagues hypothesized that external-beam 
radiotherapy could be clinically superior to brachytherapy in local control of STSs (61). 
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Neoadjuvant radiotherapy, administered as external-beam radiotherapy, was reported 
in a randomized study to be a marginally more effective than adjuvant radiotherapy 
with regards to survival: 78 % of patients who received neoadjuvant and 68 % who 
received adjuvant radiotherapy being alive at the last follow-up (p = 0.0481) (64). The 
median follow-up was 3.3 years. The same study, however, found neoadjuvant 
radiotherapy associated with more frequent wound complications (64). The difference 
in wound complications was 18 % (p = 0.01) in favour of post-operative radiotherapy, 
though the target area for radiotherapy was smaller when it was administered pre-
operatively. 
According to current recommendations at HUCH adjuvant radiotherapy is 
administered to improve local control when the tumour is removed marginally or 
intralesionally and a re-resection with a wide margin is not feasible. 
The role of chemotherapy in treatment of STSs is still disputed. A meta-analysis of 18 
randomized studies associated combination chemotherapy of doxorubicin and 
ifosfamide with an absolute risk reduction of 11 % and relative risk of 0.56 for overall 
survival (p = 0.01) in patients with a STS (65).  For metastatic recurrence, an absolute 
risk reduction of 10 % and a risk ratio of 0.61 were reported (p = 0.02). A statistical 
improvement in local control was not found. However, when including studies using 
single-agent doxorubicin, a risk ratio of 0.73 (p = 0.02) for local control was found. The 
authors pointed out that due to the toxicity of the chemotherapy, patient selection is 
vital. Synovial sarcoma is particularly responsive to chemotherapy compared to other 
STSs (66). 
Doxorubicin alone was associated with an improvement in overall survival and 
decrease in distant recurrences but not as much as when it was combined with 
ifosfamide (65). Another randomized meta-analysis however, indicated that adding 
ifosfamide would not improve 1-year survival rate, only tumour response rate (p = 
0.009) (67). They thus recommended adding ifosfamide only in cases where the 
tumour is inoperable to try to make it resectable. 
Combination chemotherapy of doxorubicin and ifosfamide is reserved at HUCH for 
patients younger than 70 years who are in good health and have a high-grade tumour. 
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In addition two of the following criteria must be fulfilled: presence of vascular invasion, 
diameter greater than 8 cm or presence of necrosis. However, for synovial sarcoma the 
diameter criterion is 5 cm. 
2.8 Treatment errors 
On clinical inspection, a STS often appear as a growing painless mass that seldom 
functionally disturb the surrounding tissue. Neither are systemic symptoms normally 
present. As a result, the correct diagnosis is often delayed or the tumour is removed 
inadequately based on clinical findings without adequate preoperative diagnostics. In a 
series of 100 patients viewed retrospectively, the median time from the onset of 
symptoms to histologic diagnosis was six months (68). A delay longer than six months 
was associated with an increased risk for metastatic disease at diagnosis (p = 0.048). 
Fifty-one percent had metastatic disease compared with 31 % in those who received 
their diagnosis within six months. The same study also reported that in those who did 
not have metastatic disease at diagnosis (n=82), a delay longer than six months 
between initial symptoms and starting of treatment was associated with worse five-
year survival (59.7 % vs 77.0 %, p = 0.04) and greater chance of metastatic spread 
during the follow-up (38.8 % vs 76.5 %, p = 0.04). 
STSs are often resected inappropriately without a proper preoperative diagnosis based 
on clinical findings. The pseudocapsule-structure of STSs represents a particularly 
tempting way of excising the tumour. However, because tumour tissue is frequently 
found outside this capsule, high rates of local recurrence are noted when the STS is 
resected inappropriately without neoadjuvant radiotherapy (19). Only 46.2 % of 
patients with inadequate local treatment did not have a local relapse in five years (27). 
Thus enucleation that is suitable for treatment of benign soft tissue tumours (STT) is an 
unacceptable treatment method for STS. 
A retrospective study of the South-East Thames region found that 40.1 % of STS were 
resected without a pre-operative biopsy while as many as 63.3 % were resected 
without any imaging of the primary tumour (69). 
Residual STS tissue was found in 59 % of re-resection specimens after an unplanned 
resection of a STS (70). Research indicates that re-resection of the tumour bed with a 
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wide margin provides similar local control as initial surgery with wide margins (71). 
Thus re-resection should be performed whenever possible after inadequate primary 
surgery. However, a second surgery with wide margins might not always be possible 
and nonetheless increases costs, prolongs treatment and can result in unnecessary 
complications. 
Additionally, postoperative hematoma after initial surgery may allow the tumour to 
spread widely and thus contaminate a large area and subsequently force an 
amputation (72). In addition a skin incision placed transversely may lead to a wider 
resection of muscles, result in poorer functional outcome and enlarge the PTV (72). 
While a biopsy should be performed before any treatment, it should not be done 
outside the final treatment centre. This is because diagnostic errors are done on 27.4 
% on biopsies in referring centres compared with 12.3 % at specialized treatment 
centres (51). In addition a bigger percentage of biopsies done at referring centres were 
not properly performed or were found inadequate. Most importantly in 36.3% of 
biopsies done at referring centres, patients required alterations in the treatment plan, 
compared with only 4.1 % at treating centres. An inappropriately placed CNB tract may 
also jeopardize limb-sparing surgery (58). 
 Thus, to obtain optimal treatment results, all STS suspect masses should be referred 
untouched to a treatment centre with a specialized STS team. Following the 
foundation of a STS group at HUCH, both overall survival and local control has 
improved (73). Superficially located tumours greater than 5 cm in diameter as well as 
any tumour located deep should be considered as STS suspect and should be referred 
to a specialized treatment centre (74). 
2.9 Aims 
In this study we aim (i) to evaluate the accuracy of core needle biopsy in diagnostics of 
soft-tissue sarcomas, (ii) to identify any diagnostic errors and their underlying reasons 
and (iii) to identify any treatment inaccuracies resulting from an incorrect pre-
operative diagnosis. 
P a g e  | 16 
 
3 Methods 
We retrieved information on all patients older than 17 years who underwent CNB for a 
STS of the extremities or trunk that was analysed at HUCH between January 1, 2000 
and December 31, 2012 from the database at the Department of Pathology. We 
identified 313 patients and searched through the pathology records on pre-operative 
biopsies and surgical specimens. We took note of (i) the pre- and postoperative 
histologic diagnosis and (ii) grade (as set by the modified Broders grading system). 
Patients were excluded from further analysis based on the following criteria: (i) 
primary lesion of STS diagnosed prior to 2000 (n=7) and (ii) lack of surgical specimen to 
confirm diagnosis (n=9). These criteria yielded a remaining total of 297 patients. 
In the remaining patients we identified all inaccuracies between the CNB and surgical 
specimen that had the potential of influencing treatment. Such inaccuracies were pre-
operative diagnoses of (i) benign or non-sarcomatous tumours that on examination of 
the surgical specimen were STSs, (ii) low-grade STSs that were high-grade STSs, (iii) 
well-differentiated liposarcomas that were any another STS subtype and (iv) any STSs 
not identified correctly as synovial sarcoma. We also obtained from the pathology 
records: the site, depth and size (as defined by the pathologist on macroscopic 
examination of the surgical specimen) of the tumours as well as any explanations of 
why the pre-operative diagnosis might have differed from the final one. 
We retrieved all histologic slides that had provided an incorrect diagnosis and had an 
experienced musculoskeletal pathologist re-evaluate them to establish whether a 
correct diagnosis could have been reached on the basis of the CNB. We were unable to 
retrieve the histologic slides of three patients due to them being stored outside HUCH 
and thus we did not evaluate the treatment they received. In addition we failed to 
retrieve the slides of two patients despite them being stored at HUCH, though these 
two patients treatment was evaluated. To try to eliminate possible bias on re-
evaluation, the pathologist was blinded. 
To determine whether the incorrect pre-operative histologic diagnosis or grade had 
had an impact on pre-operative staging and treatment we examined the patient files 
and compared the treatment they had received with present treatment guidelines. If 
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surgery with a wide margin would not have been possible even with correct diagnosis, 
the surgery was deemed correct and instead we examined whether the patients could 
have been eligible for neoadjuvant therapy. 
4 Results 
We found errors in the CNB diagnosis with potential of influencing treatment in 48 
(16.2 %) of 297 patients. Thus, in 249 (83.8 %) of 297 patients, CNB provided all 
information required for planning of definitive treatment and pre-operative staging 
according to current treatment guidelines at HUCH. The characteristics of the tumours 
with an incorrect diagnosis set by CNB are summarized in Table II. The incorrect pre-
operative diagnoses were evenly distributed between 2000−2012. 
The sensitivity for mesenchymal malignancy in this study was 93.6 %. A pre-operative 
sarcoma-suspicion was not considered diagnostic for mesenchymal malignancy. No 
low-grade STSs were falsely designated as high-grade STSs by the CNB. Though, 24 
high-grade STSs were designated as low-grade STSs by the CNB. Thus the overall 
accuracy of grading STSs (low-grade – high-grade) was 91.4 % when excluding CNB 
diagnoses of benign, sarcoma-suspect and non-mesenchymal tumours. 
In the 48 patients with diagnostic errors: 19 patients had a non-sarcomatous diagnosis 
(Table III), 24 had the grade wrongly assigned as low grade (Table IV) and five patients 
had errors in the subtype with the potential of affecting treatment (Table V). Two 
patients had errors in both subtype and grade that had the possibility of influencing 
treatment. They are listed in Table IV. 
A total of 25 treatment and staging inaccuracies were found in 18 patients in this study 
(Table II). Twelve patients had surgery with an inadequate margin while one patient 
could have been eligible for neoadjuvant chemotherapy. The remaining twelve errors 
were limited to inadequate pre-operative staging as a result of inaccuracies in the 
diagnosis set by CNB. 
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Table II Characteristics of faulty (N=48) CNB diagnoses 
Characteristics (N=48)  Number (%) 
Location   
 Proximal upper extremity 6 (12.5) 
 Distal upper extremity 3 (6.3) 
 Proximal lower extremity 25 (52.1) 
 Distal lower extremity 8 (16.7) 
 Trunk 6 (12.5) 
Depth   
 Deep 41 (85.4) 
 Superficial 7 (14.6) 
Size (cm)*   
 <5 12 (25.0) 
 5−10 19 (39.6) 
 >10 10 (20.8) 
 Unknown 7 (14.6) 
Final diagnosis   
 Angiosarcoma 2 (4.2) 
 Clear-cell sarcoma 2 (4.2) 
 Epithelioid sarcoma 1 (2.1) 
 Fibrosarcoma 1 (2.1) 
 Leiomyosarcoma 1 (2.1) 
 Liposarcoma 17 (35.4) 
 MFH 12 (25.0) 
 MPNST 2 (4.2) 
 Sarcoma NS 6 (12.5) 
 Synovial sarcoma 4 (8.3) 
Final grade   
 LG 8 (16.7) 
 HG 40 (83.3) 
Treatment errors 
(n=25) 
  
 Inadequate surgical margins 12 (26.7) 
 
No preoperative 
chemotherapy 
1 (2.2) 
 No pre-operative CT of thorax 10 (22.2) 
 
No pre-operative CT of whole 
body 
2 (4.4) 
*As defined by macroscopic examination of the surgical specimen by the pathologist 
MFH = Malignant fibrous histiocytoma; MPNST = Malignant peripheral nerve sheath 
tumour; NS= Not specified; LG = Low-grade; HG = High-grade 
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Table III List of patients with a benign (n=11), sarcoma-suspect (n=5) or malignant non-mesenchymal (n=3) diagnosis set by CNB 
 Year Location Depth 
Size‡‡ 
(cm) 
CNB diagnosis Grade CNB re-evaluation Grade Final diagnosis Grade 
Treatment 
error(s) 
* 2001 Shoulder Deep 6 Neurofibroma - Neurofibroma - MPNST 4 
Surgery, pre-op CT 
of thorax 
† 2001 Thigh Deep 3.5 Reactive process - Inflammatory MFH LG 
Inflammatory myxoid 
MFH 
2 
Surgery, pre-op CT 
of thorax 
†‡ 2001 Thigh Deep 8§§ Reactive process - Inflammatory MFH LG Inflammatory MFH 3 - 
 2001 Foot Deep 3 
Benign mesenchymal 
tumour 
- Clear-cell sarcoma NS Clear-cell sarcoma NS - 
§ 2002 Thigh Deep 10 Reactive process - Myxoid liposarcoma 2 Myxoid liposarcoma 2 Pre-op CT of body 
‖ 2002 Shoulder Deep 5 Sarcoma suspicion - Synovial sarcoma NS Spindle-cell sarcoma 4 
Surgery, pre-op CT 
of thorax 
¶ 2004 Thigh Deep 4 Reactive process - 
Tumour of unknown 
malignancy 
- MFH 4 
Surgery, pre-op CT 
of thorax 
** 2005 Groin Deep 6 Carcinoma metastasis - NE - Epithelioid sarcoma NS NE 
 2006 Groin Superficial 11.5 
Benign mesenchymal 
tumour 
- 
Benign neurogen 
tumour 
- 
Spindle-cell sarcoma 
NOS 
2 
Pre-op CT of 
thorax 
 2006 Groin Deep 5.5 
Mesenchymal tumour of 
unknown malignancy 
- Condroid lipoma - Sarcoma NOS LG - 
 2007 Elbow Deep 4.5 
Melanoma, clear-cell 
sarcoma possible 
- Melanoma - Clear-cell sarcoma HG - 
 2008 Back Deep 10 
Benign mesenchymal 
tumour 
- 
Mesenchymal tumour 
of unknown 
malignancy 
- Myxoid MFH 2 Surgery 
* 2008 Trunk Deep 5 Neuroendocrine tumour - Carcinoma metastasis - Glandular MPNST HG Surgery 
††† 2008 Breast Superficial 5§§ 
Malignant phyllodes 
tumour 
- Angiosarcoma NS Angiosarcoma NS 
Pre-op CT of 
thorax 
* 2009 Thigh Deep 5 
Benign mesenchymal 
tumour 
- 
Spindle-cell sarcoma of 
unknown malignancy 
- 
Undifferentiated 
liposarcoma 
3 
Surgery, pre-op CT 
of body 
¶†† 2009 Upper arm Deep 1.8 
Mesenchymal tumour of 
unknown malignancy 
- NE - Myxoid MFH 2 NE 
‖ 2011 Knee Deep 4 Myxoma - Myxoid liposarcoma 2 Myxoid MFH 3 
Surgery, no pre-op 
CT of thorax 
†† 2012 Breast Superficial 4.5 Fibrosis - Reactive process - Angiosarcoma NS - 
 2012 Armpit Deep 3 Malignancy suspicion - NE  Sarcoma NOS HG Surgery 
* Heterogen tumour with more than one component; † Difficult to classify even from surgical specimen; ‡ Open biopsy before surgery also indicated a reacve process; § Small abnormal ssue spot on 
CNB noted on initial examination; ‖ Small CNB specimen; ¶ Evaluation of CNB difficult; ** CNB immunohistochemistry not suing ﬁnal diagnosis; †† CNB done elsewhere; ‡‡ As reported by macroscopic 
evaluation of the surgical specimen by pathologist; §§ As reported by radiologist 
CNB = Core-needle biopsy; HG = High-grade; LG = Low-grade MFH = Malignant fibrous histiocytoma; MPNST = Malignant peripheral nerve sheath tumour; NE = Not evaluated; NOS = Not 
otherwise specified; NS = Not specified; Pre-op = Pre-operative 
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  Table IV List of patients with an incorrect low-grade soft tissue sarcoma diagnosis (n=24) set by CNB 
 Year Location Depth 
Size** 
(cm) 
CNB diagnosis Grade CNB re-evaluation Grade Final diagnosis Grade 
Treatment 
error(s) 
* 2000 Armpit Superficial 7 Sarcoma NOS LG Myxoid MFH LG 
Round-cell 
liposarcoma 
3 
Surgery, pre-op CT 
of thorax 
 2000 Groin Superficial - 
Myxoid mesenchymal 
tumour 
2 Myxoid liposarcoma 2 
Round-cell 
liposarcoma 
3 
Pre-op CT of 
thorax 
* 2000 Thigh Deep 17 Myxoid liposarcoma 2 
Round-cell 
liposarcoma 
3 
Round-cell 
liposarcoma 
3 - 
 2000 Thigh Deep 4 Sarcoma NOS LG 
Mesenchymal tumour 
of unknown 
malignancy 
- MFH 3 - 
*† 2001 Knee Deep 7†† Myxoid liposarcoma 2 
Mesenchymal tumour 
of unknown 
malignancy 
- 
Round-cell 
liposarcoma 
3 - 
‡ 2002 Leg Deep 18 Myxoid liposarcoma 2 Myxoid liposarcoma 2 
Round-cell 
liposarcoma 
3 - 
* 2002 Thigh Deep 8 Spindle-cell sarcoma NOS 2 
Spindle-cell sarcoma 
NOS 
3 
Undifferentiated 
liposarcoma 
4 - 
§ 2004 Thigh Deep 10 Sarcoma NOS LG Synovial sarcoma NS Synovial sarcoma NS - 
*‡ 2004 Thigh Deep 9.5 
Well-differentiated 
liposarcoma 
1 Myxoid liposarcoma 2 
Round- cell 
liposarcoma 
3 Surgery 
† 2004 Thigh Deep 13 Myxoid liposarcoma 2 
Round-cell 
liposarcoma 
3 
Round-cell 
liposarcoma 
3 - 
 2005 Thigh Deep 10†† Sarcoma NOS 2 
Spindle-cell sarcoma 
NOS 
3 MFH 4 - 
 2005 Wrist Deep 9.5 Sarcoma NOS LG 
Spindle-cell sarcoma 
NOS 
3 Sarcoma NOS 3 - 
‖ 2007 Thigh Deep 7.3 Leiomyosarcoma LG NE - Leiomyosarcoma 4 NE 
* 2008 Thigh Superficial 5.5†† Myxoid liposarcoma 2 
Round-cell 
liposarcoma 
3 
Round-cell 
liposarcoma 
3 - 
* 2009 Leg Deep 6 Myxoid liposarcoma 2 Myxoid liposarcoma 2 
Round-cell 
liposarcoma 
3 - 
 2009 Foot Deep 5.5 Sarcoma NOS LG 
Spindle-cell sarcoma 
NOS 
LG Fibrosarcoma 3 - 
* Heterogen tumour with more than one component; † Even small spot with grade three sarcoma found on inial inspecon of CNB; ‡ First CNB non-diagnostic; § CNB immunohistochemistry not 
suiting final diagnosis; ‖ CNB done elsewhere; ¶ Difficult to classify even from surgical specimen; ** As reported by macroscopic evaluation of the surgical specimen by pathologist; †† As reported 
by radiologist 
CNB = Core-needle biopsy; HG = High-grade; LG = Low-grade MFH = Malignant fibrous histiocytoma; MPNST = Malignant peripheral nerve sheath tumour; NE = Not evaluated; NOS = Not 
otherwise specified; Pre-op = Pre-operative 
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Table IV List of patients with an incorrect low-grade soft tissue sarcoma diagnosis (n=24) set by CNB (cont.) 
 Year Location Depth 
Size** 
(cm) 
CNB diagnosis Grade CNB re-evaluation Grade Final diagnosis Grade 
Treatment 
error(s) 
* 2009 Thigh Deep 14 Pleomorphic liposarcoma 2 
Pleomorphic 
liposarcoma 
HG 
Pleomorphic 
liposarcoma 
4 - 
 2010 Shoulder Deep 6 MFH LG Myxoid liposarcoma 2 Myxoid MFH 3 Chemotherapy 
* 2010 Thigh Deep 30 Myxoid liposarcoma 2 
Round-cell 
liposarcoma 
3 
Round-cell 
liposarcoma 
3 - 
 2011 Thigh Deep 17.5 Sarcoma NOS LG MFH LG Myxoid MFH 3 - 
* 2011 Leg Deep 4.3 Myxoid liposarcoma 2 
Round-cell 
liposarcoma 
3 
Round-cell 
liposarcoma 
3 - 
 2011 Forearm Superficial 4.2 MFH LG Myxoid MFH 3 MFH 3 - 
 2012 Shoulder Deep 2 MFH LG Myxoid MFH 2 Myxoid MFH 3 - 
¶ 2012 Thigh Deep 15 Sarcoma NOS LG Sarcoma NOS 3 Sarcoma NOS 3 - 
* Heterogen tumour with more than one component; † Even small spot with grade three sarcoma found on inial inspecon of CNB; ‡ First CNB non-diagnostic; § CNB immunohistochemistry not 
suiting final diagnosis; ‖ CNB done elsewhere; ¶ Difficult to classify even from surgical specimen; ** As reported by macroscopic evaluation of the surgical specimen by pathologist; †† As reported 
by radiologist 
CNB = Core-needle biopsy; HG = High-grade; LG = Low-grade MFH = Malignant fibrous histiocytoma; MPNST = Malignant peripheral nerve sheath tumour; NE = Not evaluated; NOS = Not 
otherwise specified; Pre-op = Pre-operative 
Table V List of patients with incorrect diagnosis of well-differentiated liposarcoma (n=2) or sarcoma other than synovial sarcoma (n=3) by CNB 
 
Year Location Depth Size‡ (cm) CNB diagnosis Grade CNB re-evaluation Grade Final diagnosis Grade 
Treatment 
error(s) 
 
2000 Thigh Deep 7 
Malignant 
hemangioperiocytoma 
- Synovial sarcoma NS Synovial sarcoma NS - 
 
2003 Leg Deep 6§ Sarcoma NOS 3 Synovial sarcoma NS Synovial sarcoma NS - 
* 2003 Thigh Deep 20 
Well-differentiated 
liposarcoma 
1 
Well-differentiated 
liposarcoma 
1 Liposarcoma 2 Surgery 
 
2004 Back Deep 7.5 Sarcoma NOS LG Synovial sarcoma NS Synovial sarcoma NS 
Pre-op CT of 
thorax 
† 2004 Thigh Deep 13 
Well-differentiated 
liposarcoma 
1 NE  Myxoid liposarcoma 2 - 
* First CNB non-diagnosc; † Heterogen tumour with more than one component; ‡ As reported by macroscopic evaluation of the surgical specimen by pathologist; § As reported by radiologist 
CNB = Core-needle biopsy; LG = Low-grade; NOS = Not otherwise specified; NS = Not specified; Pre-op = Pre-operative 
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On re-examination of the CNBs, the diagnosis was changed for a more correct one in 
26 (54.2 %) of 48 patients. Five patients with a pre-operative diagnosis of a benign or 
non-mesenchymal tumour, twelve patients with a pre-operative diagnosis of a low-
grade STS and three patients whose synovial sarcoma was not recognized correctly 
pre-operatively had their pre-operative diagnosis changed to the correct diagnosis. In 
addition, two patients with a benign diagnosis and one with a well-differentiated 
liposarcoma had their pre-operative diagnosis changed to a low-grade tumour though 
their final diagnosis was a high-grade STS. Three tumours were considered suspicious 
for malignancy with the original pre-operative diagnosis of a benign tumour. In 
addition two patients had their pre-operative diagnosis changed from a STS to a 
possibly malignant tumour. 
STSs with a myxoid nature constituted 20 (41.7 %) of 48 of the erroneous CNB 
diagnoses: 13 of these were liposarcomas and seven were MFHs. In eleven myxoid 
liposarcomas, the errors were limited to not recognizing the presence of round-cell 
liposarcoma pre-operatively. In three CNBs of myxoid liposarcoma, the pathologist 
originally identified a small area that he pointed out could represent an area of higher 
malignancy. Tumour heterogeneity was additionally noted in the pathology reports of 
two MPNSTs, one MFH, one pleomorphic and two undifferentiated liposarcomas. 
In four patients, the pathologist noted that the CNB was not optimal for diagnosis. 
Another four patients had tumours that were challenging to accurately specify even 
from the surgical specimen. Two of these were inflammatory MFHs, one was an 
angiosarcoma and one was an unspecified high-grade sarcoma. Though, on re-
evaluation the pathologist was able to make the correct diagnosis in all but one of the 
patients with an inflammatory MFH where the grade was incorrectly assigned. In three 
other patients the pathologist had originally suggested the correct diagnosis 
(epithelioid sarcoma, clear-cell sarcoma and synovial sarcoma) as plausible but that the 
profile was more suited for another diagnosis. 
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5 Discussion 
The findings in our study support the belief that CNB is very accurate for identifying 
mesenchymal malignancy (93.6 %) and differentiating low-grade STSs from high-grade 
STSs (91.4 %) using a modified Broders-grading system (1). Most importantly we found 
that CNB provides correct information for planning of definitive treatment in 83.3 % of 
patients when evaluated by an experienced STS pathologist. Interpreting CNBs of 
myxoid STSs was associated with a significant challenge: 20 (41.7 %) of the 48 
erroneous diagnoses had a myxoid stroma. 
While this is one of the largest studies on the accuracy of CNB in diagnostics of STSs, 
the lack of benign STTs is problematic. Firstly, we are unable to confirm that we do not 
“over-diagnose” our patients, thus obtaining higher rates for mesenchymal malignancy 
but simultaneously "over-treating” benign STT. However, no low-grade STSs were 
diagnosed as high-grade STSs by CNB. Secondly, because we only re-evaluated CNBs 
that had provided an incorrect diagnosis, it is possible that the pathologist may have 
been more eager to interpret the slides as more malignant than he normally would. 
Thus, the 26 diagnoses we obtained on re-evaluation may not be obtainable in clinical 
practice. The lack of any background information on the patients and their STSs may 
have also influenced the diagnosis we obtained on re-evaluation. In certain patients 
this could have provided information that could have altered the final CNB diagnosis. 
Because we are unable to calculate the statistical significance of our findings from the 
material we collected, we cannot confirm whether myxoid STSs were truly more often 
misdiagnosed. Neither can we evaluate whether other factors were risk factors for 
misdiagnosing STSs. Also, our study does not answer whether complications occur in 
CNB of STSs and if these affect subsequent treatment. 
Our results compare favourably to other studies. In the two largest studies on the 
accuracy of CNB in diagnosis of STSs with 180 and 225 STS patients, sensitivity rates for 
mesenchymal malignancy of 99.4 % and 96.3 % were reported (43, 48), while grading 
accuracies of 84.9 % and 86.3 % were reported respectively. The fact that our study 
had a lower sensitivity for mesenchymal malignancy but a higher grading accuracy is 
somewhat surprising. However, Hoeber and colleagues excluded non-diagnostic CNB 
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specimens and had more false-positive diagnoses for mesenchymal malignancy than 
false-negatives (43). Different grading systems used may have also explained the 
differences. Strauss and colleagues used the FNCLCC system (48) while Hoeber and 
colleagues did not specify the grading system used. Image-guided CNB specimens were 
excluded by Strauss and colleagues and they included all palpable STSs regardless of 
location. It is possible that smaller tumours, from which obtaining adequate material is 
challenging (35), were excluded, thus affecting accuracy rates. 
It is probable that open biopsy would have provided better sensitivity for 
mesenchymal malignancy and better grading accuracy than CNB in our patients, 
because accuracy rates from 95 to 100 % are reported in literature for diagnosis of 
STTs by open biopsy (21, 40, 43, 49, 50). However, open biopsy is associated with a 
high complication rate (15.9 %) and open biopsy affected subsequent treatment 
negatively in 16.6 % of patients (51). Additionally, open biopsy is time-consuming and 
expensive. Thus we consider that open biopsy should never be the primary method of 
choice for diagnosis of STS suspect tumours. 
Studies evaluating FNAC have reached similar sensitivity rates for mesenchymal 
malignancy (54, 55, 56) and grading (55) as we did for CNB in our study. However, 
these studies excluded inadequate specimens and included local and metastatic 
recurrences. Thus the accuracy rates obtained in these studies are not directly 
comparable to our results. 
Kilpatrick and colleagues recommended FNAC for diagnosis of STSs when on-site 
evaluation of the specimen is available (54). Otherwise they thought CNB would be 
superior to ensure adequate tissue for further study. We believe CNB may be slightly 
more sensitive in recognizing STSs than FNAC and more accurate at grading STSs. 
Domanski and colleagues reported how FNAC and CNB supplemented each other in 
the diagnostics of STSs (53). In seven patients CNB was inconclusive while FNAC 
enabled diagnosis and in three patients the diagnosis was set on the basis of the CNB 
because FNAC was inconclusive. Thus obtaining both a CNB and FNAC specimen from 
STS suspect tumours is recommended, though FNAC results are of limited value at 
HUCH. 
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Heterogeneous and myxoid STSs, which were often misdiagnosed or graded in our 
study, are recognized as adverse factors for correct diagnosis in literature. A study 
reported that adequate tissue is only obtained from 81.4 % of heterogeneous tumours, 
compared to 97.5 % of homogeneous tumours (p = 0.0036) (33). CNBs of non-myxoid 
tumours were more often useful for diagnosis (80 %) than CNBs of myxoid tumours (11 
%, p = 0.001) (30). Higher rates of diagnostic errors were also found in another study in 
CNBs of myxoid tumours compared to non-myxoid tumours (p = 0.021) (29). 
Treatment inaccuracies were sparse and occurred in only 18 patients. In five patients 
errors were confined to pre-operative imaging and staging. While single-stage surgery 
is preferable to maximise patient comfort and to minimize the risk for complications, 
re-resection of the tumour after initial inadequate surgery results in comparable rates 
of local recurrence and overall survival (71). However, the possibility for neoadjuvant 
chemotherapy was lost in a patient, thus possibly affecting outcome negatively. 
Most diagnostic errors were related to rare tumour subtypes and inadequate sampling 
of tumour tissue from heterogeneous and myxoid tumours.  CNBs of myxoid STSs were 
challenging to interpret correctly with 20 (41.7 %) of the 48 of the erroneous diagnoses 
being myxoid. Thirteen were myxoid liposarcomas, though eleven of these were 
correctly recognized, but the presence of round-cell liposarcoma was not noted. Thus 
they were graded incorrectly. The presence of merely 5 % of the round-cell component 
in a myxoid liposarcoma is associated with worse outcome and these tumours should 
be treated as high-grade STSs (75). Tumour heterogeneity was additionally noted in six 
sarcomas. Thus sampling tumour tissue from multiple locations is required for the 
correct diagnosis and grading of myxoid and heterogeneous STSs. 
CNB specimens of certain uncommon STS subtypes appeared as challenging to 
interpret, thus emphasising the requirement for an experienced STS pathologist. The 
fact that certain surgical specimens were hard to evaluate emphasizes this point. 
Immunohistochemistry and genetic analysis are important ancillary techniques in 
diagnostics of STSs (6). It is very possible that some STSs in our study could have been 
correctly diagnosed with CNB if the pathologist had asked for correct ancillary studies. 
In our study, four synovial sarcomas had an incorrect pre-operative diagnosis. For 
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synovial sarcoma epithelial markers are often positive and a chromosome 
translocation t(X;18)(p11.2;q11.2) is present in most synovial sarcomas (6). All four 
CNBs were on re-evaluation suspicious for synovial sarcoma. Thus it is very possible 
that the correct diagnosis could have been reached in all four patients. In one patient, 
however, the immunohistochemical profile was not suited for synovial sarcoma. No 
synovial sarcomas have been incorrectly diagnosed since 2004, thus raising the 
possibility that these STSs are nowadays correctly identified from CNBs. 
Two angiosarcomas, clear-cell sarcomas and one epithelioid sarcoma were incorrectly 
diagnosed as benign or non-mesenchymal tumours from the CNB in our study. For 
these sarcomas there are known immunohistochemical markers and a chromosome 
translocation t(12;22)(q13;q12) that can be used to identify clear-cell sarcoma (6). 
While both angiosarcomas and one clear-cell sarcoma were recognized on re-
evaluation of the CNBs, the pathologist was unable to recognize one of the clear-cell 
sarcomas and we did not obtain the CNB of the epithelioid sarcoma. 
Our study suggests that even higher accuracy rates for mesenchymal malignancy and 
grade can be achieved than the original ones we observed. Twenty-six patients got a 
more correct diagnosis on re-evaluation and in 20 patients the new diagnosis was able 
to provide all information for planning of definitive treatment. Most importantly seven 
STSs, not recognized as such by the CNB, were identified as mesenchymal malignancies 
and five of these were graded correctly on re-evaluation of the CNB. In addition three 
CNBs of benign tumours were considered STS suspect. Consequently, an additional 
four patients would have probably undergone single-stage surgery with a wide margin. 
Image-guided CNB is highly sensitive for identifying mesenchymal malignancy and 
grade when performed at our institution, with few patients with STSs treated 
inadequately. We recommend image-guided CNB as the primary method for diagnosis 
of STSs but advise caution in evaluating CNB specimens of tumours with a myxoid 
nature. Due to the challenge of interpreting CNBs of STSs, we suggest concentrating 
STS suspicious CNB specimens to experienced STS pathologists to maximise diagnostic 
accuracy and avoid subsequent incorrect treatment. 
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